Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NILG-AML 02/06 phase III trial of standard-dose versus high-dose induction and autologous post-remission strategies in adult AML
2006-003817-42Phase 3Completed
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Dec 2006
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cytarabine, idarubicin, etoposide, busulfan, cyclophosphamide and 1 more in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by Papa Giovanni XXIII Hospital. Primary endpoints: Complete remission rate after cycle 1 and Disease-free survival. Started Dec 2006; status: completed.
02
Drugs
cytarabineidarubicinetoposidebusulfancyclophosphamide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2006-003817-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003817-42.